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Abstract
Background: The aim in this study was to investigate the effect of vitamin D (25(OH)D3) supplementation on heat
shock protein 60 (HSP 60) and other inflammatory markers (IL-17, TNF-α, PAB) in patients with coronary heart
disease (CHD).
Methods: In this double-blind, randomized clinical trial, we recruited 80 male and female patients aged 30–60 with
CHD and 25(OH)D3 serum levels < 30 ng/ml from Rasool-e-Akram Hospital in Tehran, Iran. Serum levels of HSP 60
as primary outcome, and 25(OH)D3, IL-17, TNF-α, PAB, lipid profiles and parathyroid hormone (PTH) as secondary
outcomes were measured at baseline and post-intervention. We randomly assigned eligible participants to a
placebo group (N = 40) or an intervention group (N = 40) (50,000 IU/wk. vitamin D supplement) for eight weeks.
Results: The results demonstrated that vitamin D supplementation resulted in a significant increase in 25(OH) D3
serum levels in the intervention group compared to the placebo group (46.86 vs. 7.28 ng/ml). PTH levels decreased
in the intervention group compared to the placebo group (− 19.81 vs. 2.92 pg/ml) after eight weeks of
supplementation. Furthermore, we observed a significant change in waist circumference (− 0.97 vs. -0.26 cm), fat
percentage (−.13 vs. 0.1%), systolic blood pressure (− 3.85 vs. -2.11 mmHg) and diastolic blood presure (− 4 vs. -1.
86 mmHg) in the vitamin D group compared to the placebo group (all P values < 0.05). Other variables did not
significantly change after the intervention.
Conclusion: Based on our findings, weekly vitamin D supplementation of 50,000 IU for eight weeks in patients with
CHD resulted in decreased systolic and diastolic blood pressure, waist circumference and fat percentage. No
significant effect on HSP 60, inflammatory markers or lipid profiles was observed.
Trial registration: IRCT, IRCT201612122365N14. Registered 12 December 2016.
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Background
Cardiovascular disease (CVD) is one of the main causes
of mortality and morbidity worldwide. Between 2011
and 2012, the direct and indirect costs of CVD and
stroke were $316.6 billion in the US [1]. Coronary heart
disease (CHD) accounts for the highest proportion of
health care costs in the US, with more than 1 million
hospitalizations per year [2]. In the Eastern Mediterra-
nean region, 1.4 million deaths due to CVD occurred in
2015. In addition, disability adjusted life years (DALY)
rates for CVD are higher than the global average in the
Eastern Mediterranean region [3]. Atherosclerosis is the
major cause of CVD. Even though the actual mechanism
involved in the initiation of atherosclerosis remains un-
known, there is a close correlation between inflamma-
tion and atherosclerosis both in the very early stages of
atherosclerosis and in its progression [4]. The inflamma-
tory cascade can be initiated by environmental or car-
diovascular risk factors. Some cardiovascular risk factors
are hemodynamic stress, sustained hyperlipidemia,
homocysteinemia, smoking, inflammatory mediators and
infection [4, 5]. Consequently, the inflammatory proced-
ure may overlap plaque formation, endothelial injury
and rupture [4].
Atherosclerotic lesions have been reported to increase
the levels of growth factors and proinflammatory cyto-
kines, such as HSPs [6]. HSPs are recognized according
to their molecular weights as 110, 90, 70, 60, 40 kDa and
lower molecular weights [7]. Under normal circum-
stances, HSPs play the role of molecular chaperones [8].
However, their production increases in stressful condi-
tions, such as CVD, hypertension, systemic lupus erythe-
matosus and dementia [9]. Classic atherosclerosis risk
factors lead to the expression of endothelial HSP 60s
and adhesion molecules. Because T cells respond to the
HSP 60s from the beginning of atherogenesis, the pres-
ence of HSP 60 can be considered a ‘danger signal’ for
both cellular and humoral defense response [10]. More-
over, some inflammatory markers, such as IL-17 [11]
and TNF-α [12], participate in the pathogenesis of
atherosclerosis.
Vitamin D is one the most common nutrients in stud-
ies on cardiovascular health. In addition to the pivotal
role of vitamin D in muscloskeletal health via the metab-
olism of calcium, this vitamin may affect cardiovascular
health via anti-inflammatory activity [4]. It has been esti-
mated that approximately 50% of the world’s population
has a vitamin D deficiency [13], and it has been sug-
gested that this deficiency may increase the incidence of
CVD worldwide [14, 15]. Vitamin D receptors are ubi-
quitous in all cells involved in atherosclerosis, such as
vascular endothelial and immune cells [16].
It is thought that vitamin D prevents atherosclerosis
through different mechanisms, such as the stimulation
of nitric oxide bioavailability, the inhibition of smooth
muscle proliferation in the endothelium and vascular
calcification [17]. However, according to our knowledge,
no study has been conducted on the effect of HSP 60.
Therefore, the purpose of this study was to evaluate the
effect of vitamin D supplementation on serum HSP 60
levels in patients with CHD.
Methods
Study design, participants and sample size
This randomized, placebo-controlled, double-blind trial
was conducted at Rasool-e-Akram Hospital, Tehran,
Iran from December 2016 to March 2017 during the au-
tumn/winter months. The inclusion criteria were average
age of 30–60 and a diagnosis CHD by a cardiologist.
The exclusion criteria were BMI > 35 kg/m2; a
25(OH)D3 serum level > 30 ng/ml; any diseases such as
cancer, myocardial infarction (MI), diabetes, liver or kid-
ney disorders; the intake of any medication outside the
treatment protocol; the intake of any nutritional supple-
ment (oral and/or intravenous) in the previous four
months; the intake of any herbal remedy; the routine
consumption of vitamin D-fortified foods; pregnancy or
lactation; smoking; and alcohol consumption. Our study
population consisted of 40 participants in each group.
We calculated the sample size by using G * Power 3 soft-
ware. Cohen’s effect size was 0.7 for mean difference in
the standard deviations. Among 110 enrollments, 80
males and females were eligible to participate the study.
Eighty participants were randomly assigned in either pla-
cebo or vitamin D group (40 subjects in each group)
after signing the consent form. The primary outcome of
our study was HSP 60, and the secondary outcomes
were Interleukin17 (IL17), Pro-oxidant-antioxidant Bal-
ance (PAB), TNF-alpha, low density lipoprotein (LDL)
and high-density lipoprotein (HDL) cholesterol, an-
thropometric measurements (weight, Height, BMI, waist
circumference, fat percentage), systolic and diastolic
blood pressure. Prescreening of coronary heart disease
was done by cardiologist in the first visit, and other in-
clusion and exclusion criteria were evaluated by our nu-
tritionist. The study was approved by Ethical Committee
of Iran University of Medical Sciences (Reference Num-
ber 28891), and was registered at the Iranian Registry of
Clinical Trials (http://www.irct.ir) with the identification
Number of IRCT201612122365N14.
Randomization and intervention
We applied the block randomization method with quad-
ruple blocks for randomized sampling. According to the
sample size, 20 blocks were generated using (http://
www.sealedenvelope.com) website. We filled similar
boxes with vitamin D or placebo, and printed distinct
random number on each box. For the sake of
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confidentiality of subjects’ information and blindness of
the study, an outsider staff handed the boxes to the sub-
jects according to the number of randomization. We
followed up the subjects’ compliance by weekly phone
calls.
Participants of the intervention group, received
50,000 IU cholecalciferol, and other 40 subjects of the
placebo group took matching placebo (Zahravi pharm.
Co; Tehran, Iran) for 8 weeks. Participants were advised
to take their supplements once a week preferably with
their lunch. Consumption of 50,000 IU vitamin D per
week was considered to be safe since the upper limit is
10,000 IU/d [18].
Anthropometric assessments and blood pressure
At the baseline and after the 8-week intervention period,
anthropometric characteristics and blood pressure were
measured with the same measurement tools and staff.
Height was measured using a wall-mounted stadiometer
with the nearest 0.1 cm. Weight and fat percentage were
determined with a digital scale to the nearest 0.1 kg
(Beurer, GmBH, Ulm, Germany). BMI was calculated as
weight divided by the square of height (kg/m2). Waist
circumference (WC) was measured at the approximate
midpoint between the lower border of the last palpable
rib and iliac crest in a standing position at the point of
minimal waist via non-elastic meter to the nearest
0.1 cm. Blood pressure was measured 3 times at 5-min
intervals in the seated position with both feet flat on the
floor, after a 10-min rest, using a digital sphygmoman-
ometer (Omron M3, Kyoto, Japan).
Biomarkers analysis
Blood samples were collected at the baseline and after
8th-week intervention. Sera were separated from blood
samples by 3000 g centrifugation in the room
temperature and were kept in − 80 °C until analysis.
Lipid profiles were measured with enzyme kits (Fara-
samed Co., Tehran, Iran) by an auto-analyzer (BT 1500).
Serum level of 25-hydroxy vitamin D3 (25-(OH) D3) was
evaluated by human ELISA kit (EUROIMMUN,
Germany, cat.NO: EQ. 6411–9601). We categorized vita-
min D status according to the following reference range:
serum 25(OH) D3 levels < 10(ng/mL) as severe defi-
ciency, 10–20(ng/mL) as deficiency, 20–30(ng/mL) as
insufficiency, and > 30(ng/mL) as sufficiency [19]. Fur-
thermore, the human ELISA kits of HSP 60 (ZellBio
GmbH, Germany, cat.NO: ZB-11774S-H9648), IL-17
(ZellBio GmbH, Germany, cat.NO: ZB-10142S-H9648),
TNF-α (IBL, Hamburg, Germany, cat.NO: BE55181),
and PTH (EUROIMMUN, Germany, cat.NO: EQ. 6421–
9601) were used to evaluate biomarkers. Serum concen-
tration of PAB was measured based on the previous
study protocol [20].
Dietary intake, physical activity and sun exposure
We evaluated sun exposure, physical activity, and dietary
status both at baseline and post-intervention. We asked
the subjects about the duration of sun exposure in mi-
nutes per hours of a routine day in the recent week. Ac-
cordingly, the duration of sun exposure was categorized
as 0–10 min; 10 min–1 h; 1–2 h; and more than 2 h.
We asked them about the exact time of exposure as well:
7 am–10 am, 10 am–3 pm, and 3 pm–5 pm. For autumn
and winter days, we only considered the duration of sun
exposure between 10 am and 3 pm. Furthermore, the
participants were asked which parts of their body were
exposed to sunlight and whether they used sunscreen or
not. Physical activity (Met-Min/week) level was mea-
sured by the standardized short-form of the Inter-
national Physical Activity Questionnaire (IPAQ) in
Persian [21]. We evaluated Dietary intakes by 2-day food
recall forms (1 usual day and 1 holiday) and the Nutri-
tionist IV software program (First Databank Inc., Hearst
Corp., San Bruno, CA, USA).
Statistical analysis
We tested normal distribution via Kolmogorov-Smirnov
with P value of 0.05. We tested between-group differ-
ences by independent sample t-test and Mann-Whitney
U test as the parametric and nonparametric tests re-
spectively. Between-groups variance was assessed by
analysis of covariance (ANCOVA) for weight, BMI, en-
ergy, dietary calcium, vitamin D intake, sun exposure,
physical activity, and baseline values as covariates. Be-
sides, paired t test and nonparametric Wilcoxon
signed-rank test were applied for assessing within-group
differences (TNF-α, PAB, 25(OH) D3, LDL, HDL, TC,
TG, PTH, Energy, Vitamin D, Calcium, BMI, WC,
Weight, Fat percentage, Systolic blood pressure, Dia-
stolic blood pressure). For comparing the difference be-
tween observed and expected frequency we ran
Chi-square test. All statistically significant analyses were
run in SPSS (ver. 24; SPSS Inc. Chicago IL USA).
A P value less than 0.05 was considered significant.
Results
Participants’ enrolment
Among 110 enrolled participants, 80 subjects were
eligible for inclusion, and 67 patients completed
8 weeks follow up. We didn’t receive any reports of
adverse side effects or vitamin D toxicity symptoms
during the trial. [Fig. 1].
Demographic characteristics
The mean age of the participants was 56 years. Ap-
proximately, most of the subjects were males (71.9%
in vitamin D and 77.1% in placebo group), and most
of them were employed (59.4% in vitamin D and
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57.1% in placebo group). At baseline, there were no
differences between placebo and intervention groups
(p > 0.05). [Table 1].
Vitamin D supplementation had no effect on HSP
60 serum concentration (p > 0.05). IL-17, TNF-α, PAB
and Lipid profiles did not change significantly within
and between groups. There was a significant decrease
in PTH level (− 19.81 vs. 2.92 pg/ml) (p = 0.003), and
a dramatic increase in 25(OH) D3 serum levels in
intervention group and the modest increase in pla-
cebo group (46.86 vs. 7.28 ng/ml) (p < 0.001 vs
0.016). Dietary factors including energy, vitamin D,
and calcium did not significantly differ between and
within 2 groups at the baseline vs after 8 weeks inter-
vention (p > 0.05). Anthropometric characteristics and
blood pressure are represented in Table 2. BMI and
weight did not change significantly after intervention
(p > 0.05). Waist circumference (− 0.97 vs. -0.26 cm)
(p = 0.005), systolic (− 3.85 vs. -2.11 mmHg) (p =
0.009) and diastolic blood pressure (− 4 vs.
-1.86 mmHg) (p = 0.010), and fat percentage (− 1.13
vs. 0.1%) (p = 0.029), decreased significantly in vitamin
D group after intervention. Whereas, diastolic blood
pressure of placebo group attenuated after the inter-
vention [Table 2].
Hours of exposure to sunlight and physical activity did
not differ significantly between groups at the baseline
and post intervention. (p > 0.05) [Table 3].
Discussion
According to the results of our study, vitamin D supple-
mentation increased serum vitamin D levels comparing
placebo group. However, HSP-60 did not change signifi-
cantly after intervention (p = 0.08). Oral intake of
50,000 IU vitamin D once a week for 8 weeks a standard
protocol for treatment of severe and moderate vitamin
D deficiency, and no adverse effects have been reported
in human studies for this recommendation [19, 22].
Various interventional and cross-sectional studies have
been carried out in this field and have yielded concord-
ant results from our study [23–25].
HSP 60
There was no significant difference between HSP 60
levels in placebo group and vitamin D group before and
after intervention. Oxidative stress, infection, heat, and
immune diseases may stimulate body production of HSP
60, and conclusively increase inflammatory complica-
tions [26]. Various studies have suggested that vitamin D
may reduce oxidative stress [27], which decreases HSP
Fig. 1 Flow chart. Of the 110 subjects assessed for eligibility 67 completed the study stages
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60 production. However, the results of our research, rep-
resented controversial results about the association of
vitamin D and HSP 60.
Inflammatory markers
Our Findings indicated no significant differences in
serum levels of inflammatory markers within and be-
tween groups. Various studies have been conducted
on the effect of vitamin D supplementation on in-
flammation. In line with the results of our study,
Witham and coworkers reported no differences in
TNF-α, among MI patients (N = 74) treated with sin-
gle dose of 100,000 IU vitamin D comparing placebo
group [28]. Nonsignificant results may have been due
to low bioavailable dose of vitamin D in each inter-
vention episode. Similarly, Jorde and colleagues indi-
cated that vitamin D supplementation didn’t have
any effects on IL-17 and other inflammatory markers
in patients with overweight and obesity [29]. In con-
trast, Schleithoff and coworkers compared the effect
of 50 μg vitamin D plus 500 mg calcium versus pla-
cebo in a daily manner for 9 months, among 93
CHD patients. They found that TNF-α (inflammatory
marker) decreased, and IL-10 (anti-inflammatory
marker) increased significantly after vitamin D inter-
vention [30]. The inconsistent results may be related
to baseline vitamin D status/25(OH)D concentrations
of study subjects, intervention dose, length of inter-
vention, bioavailability of supplements, and added ef-
fect of calcium.
PAB
In the current study, there was no significant association
between vitamin D supplementation and PAB. Asemi
and colleagues investigated the effect of 50,000 IU vita-
min D comparing placebo on total Antioxidant Capacity
(TAC) among 54 patients with Gestational diabetes mel-
litus (GDM) and vitamin D deficiency. No relationship
was found between vitamin D supplementation and oxi-
dative stress levels. These results may have been due to
low baseline levels of oxidative stress [27]. In contrast,
Anandabaskar and coworkers demonstrated that weekly
supplementation of 60,000 IU vitamin D for 8 weeks
among 70 males and females with type 2 diabetes may
decrease malondialdehyde (MDA) and TAC levels [31].
Lipid profiles
Vitamin D may affect lipid profiles by reducing intestinal
absorption of lipids, endogenic lipid synthesis, stimulat-
ing lipolysis, and improving lipid metabolism [32]. Vita-
min D may improve insulin activity that prevents
metabolic syndrome [32]. Furthermore, vitamin D may
inhibit bile acid synthesis which results in decreased
cholesterol levels [32]. However, we did not find any sig-
nificant results around improvement of lipid profiles.
The results of our study are along with some other pre-
vious studies which failed to demonstrate any significant
association between increased serum level of vitamin D
and improvement of the lipid profiles [33–35].
Non-significant results may have been because of nor-
mal concentration of lipid profiles at the baseline. On
the other side, Salekzamani and coworkers demonstrated
Table 1 Baseline Characteristics of the Study Participants
Placebo (35 patient) Vitamin D (32 patient) P value
Agea 56.00 (46, 60) 56.00 (53, 59.75) 0.7171
Weight (kg) 82.12 (10.07) 79.01 (11.17) 0.2332
Height (cm) 168.8 (8.3) 167.8 (7.9) 0.6332
BMI (kg/m2) 28.4 (3.37) 27.05 (3.68) 0.3012
WC (cm) 94.17 (10.29) 92.43 (12.48) 0.5362
Fat percentage (%) 32.65 (4.57) 33.97 (6.45) 0.3322
Systolic blood pressure (mmHg) 126.51 (12.70) 129.00 (15.82) 0.4792
Diastolic blood pressure (mmHg) 80.14 (8.7) 79.93 (10.61) 0.9312
Gender
Male, Frequency (%) 27 (77.1) 23 (71.9) 0.6213
Female, Frequency (%) 8 (22.9) 9 (28.1)
Job
Employed, Frequency (%) 20 (57.10) 19 (59.40) 0.7743
Unemployed, Frequency (%) 5 (14.30) 6 (18.70)
Retired, Frequency (%) 10 (28.60) 7 (21.90)
aFor descriptive statistics, we used Man-Whitney test for Between groups comparisons (Median (IQR)). 1Statistical significance is based on Man-Whitney test,
2Statistical significances are based on independent t-test (Mean (SD)), 3Statistical significances are based on Chi-square test. BMI, Body Mass Index; WC,
Waist Circumference
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that 50,000 IU/week vitamin D for 16 weeks resulted in
descending Triglyceride (TG) levels in 80 subjects with
vitamin D deficiency and metabolic syndrome [36].
Table 2 Biochemistry Tests Dietary Intake, Anthropometric
Characteristics and Blood Pressure at the Baseline and After
Intervention
Placebo (35 patient) Vitamin D (32 patient) P value2
HSP 60a (ng/l)
Baseline 599.40 (478.80, 1089.00) 603.15 (498.12, 1416.50) 0.880
Endpoint 765.40 (566.80, 1450.00) 649.20 (453.57, 1138.25) 0.142
P value1 0.083 0.104
IL17a (ng/l)
Baseline 77.70 (69.50, 183.50) 86.55 (76.27, 122.52) 0.251
Endpoint 82.00 (70.70, 161.20) 77.00 (69.30, 130.80) 0.585
P value1 0.187 0.183
TNFα (pg/ml)
Baseline 2.18 (01.86) 2.10 (1.62) 0.894
Endpoint 2.79 (2.68) 3.04 (3.48) 0.734
P value1 0.095 0.111
PAB (HK)
Baseline 148.02 (69.07) 168.56 (71.39) 0.236
Endpoint 149.89 (65.54) 166.50 (62.29) 0.293
P value1 0.820 0.866
25(OH) D3 (ng/ml)
Baseline 17.26 (6.95) 16.62 (7.46) 0.717
Endpoint 27.54 (25.88) 63.48 (25.86) < 0.001
P value1 0.016 < 0.001
LDL (mg/dl)
Baseline 81.48 (22.17) 89.37 (26.78) 0.192
Endpoint 80.34 (29.41) 84.28 (29.49) 0.586
P value1 0.722 0.162
HDL (mg/dl)
Baseline 37.68 (7.42) 35.81 (7.50) 0.308
Endpoint 35.68 (9.94) 34.96 (7.54) 0.743
P value1 0.163 0.459
TC (mg/dl)
Baseline 124.05 (29.89) 134.37 (33.05) 0.184
Endpoint 124.77 (37.01) 128.09(38.08) 0.719
P value1 0.858 0.153
TG (mg/dl)
Baseline 136.48 (75.73) 154.50 (89.96) 0.377
Endpoint 153.02 (80.01) 172.37 (98.19) 0.382
P value1 0.160 0.124
PTH (pg/ml)
Baseline 37.80 (15.08) 43.35 (23.31) 0.258
Endpoint 40.72 (22.61) 23.54 (17.10) 0.248
P value1 0.306 0.003
Energy (cal)
Baseline 1733.28 (297.96) 1859.48 (327.65) 0.103
Table 2 Biochemistry Tests Dietary Intake, Anthropometric
Characteristics and Blood Pressure at the Baseline and After
Intervention (Continued)
Placebo (35 patient) Vitamin D (32 patient) P value2
Endpoint 1776.27 (292.26) 1889.46 (298.51) 0.122
P value1 0.403 0.617
Vitamin Da (ug)
Baseline 1.34 (0.08, 2.64) 0.94 (0.36, 2.14) 0.660
Endpoint 1.56 (0.96, 2.61) 1.39 (0.66, 2.41) 0.514
P value1 0.647 0.121
Calcium (mg)
Baseline 720.13 (250.60) 723.90 (217.96) 0.948
Endpoint 807.77 (243.86) 785.90 (244.23) 0.715
P value1 0.108 0.266
BMI (kg/m2)
Baseline 28.4 (3.37) 27.05 (3.68) 0.301
Endpoint 28.31 (3.34) 27.37 (3.64) 0.276
P value1 0.475 0.423
WC (cm)
Baseline 94.17 (10.29) 92.43 (12.48) 0.536
Endpoint 93.91 (10.38) 91.46 (12.62) 0.388
P value1 0.324 0.005
Weight (kg)
Baseline 82.12 (10.07) 79.01 (11.17) 0.233
Endpoint 81.85 (9.69) 78.27 (70.79) 0.158
P value1 0.319 0.103
Fat percentage (%)
Baseline 32.65 (4.57) 33.97 (6.45) 0.332
Endpoint 32.75 (4.81) 32.84 (5.79) 0.943
P value1 0.729 0.029
Systolic blood pressure (mmHg)
Baseline 126.51 (12.70) 129.00 (15.82) 0.479
Endpoint 124.4 (8.29) 125.15 (14.16) 0.796
P value1 0.146 0.009
Diastolic blood pressure (mmHg)
Baseline 80.14 (8.7) 79.93 (10.61) 0.931
Endpoint 78.28 (7.46) 75.93 (8.74) 0.240
P value1 0.003 0.010
a For descriptive statistics, Man-Whitney test was used for between-groups
comparisons (Median (IQR)). Wilcoxon test was used for within-groups
comparisons (Mean (SD)).1Within-group P values based on paired t-test, 2
Between group P values based on t-test. 3 Post-intervention between-group P
value based on ANCOVA with baseline value of each variable and BMI as
covariates. HSP 60, IL17, Interleukin 17; TNFα Tumor necrosis factor α, PAB Pro
oxidant Anti-oxidant Balance, LDL Low density lipoprotein, HDL High Density
Lipoprotein, TC Total Cholesterol, TG Triglyceride, PTH Parathyroid Hormone,
BMI Body Mass Index, WC Waist Circumference
Bahrami et al. Nutrition & Metabolism  (2018) 15:56 Page 6 of 9
PTH
vitamin D deficiency leads to hyperactivity of parathy-
roid gland to compensate for lack of vitamin D, as the
result of which PTH level increases [37]. In the current
study, vitamin D supplementation represented a signifi-
cant decrease in PTH level after vitamin D intervention.
According to the results of previous studies, increased
levels of parathyroid hormone may lead to the transfer
of large amounts of calcium into cardiomyocyte and can
lead to death of these cells and damage to the heart tis-
sue. Also lead to contractions and tightness of vessels in
the smooth muscle of vascular endothelium wall that
can be effective in boosting blood pressure. Therefore,
supplementation of vitamin D that can reduce parathy-
roid hormone levels may be effective in improving car-
diovascular health [38].
Anthropometric measurements, dietary intake, physical
activity and sun exposure
The covariates of this study were weight, BMI, WC,
body fat percentage, dietary intake of energy, vitamin D,
calcium, physical activity, and sun exposure. WC and
body fat percentage represented significant decrease in
vitamin D group after the intervention. Mean systolic
and diastolic blood pressure significantly decreased in
vitamin D group after the intervention. On the other
side, diastolic blood pressure was significantly lower
within placebo group comparing baseline and endpoint.
Blood pressure
Various observational studies have reported an inverse
association between vitamin D levels and blood pressure
[38–40]. The probable biological mechanisms for afore-
mentioned studies may be related to the expression of
vitamin D receptors on the surface of endothelial
cells, smooth muscle cells, and myocytes [41–43].
Furthermore, vitamin D may improve endothelial
function and decrease production of pro-inflammatory
cytokines, renin-angiotensin system activity, and PTH
level [38, 44].
Strengths and limitations
We applied the safe and sufficient dose of vitamin D,
which could replace serum level of 25 (OH) D3 cor-
rectly. Moreover, based on our information this study
was conducted for the first time. We controlled the
study for potential confounding factors as well. However,
our study had some limitations such as short study
period, using the ELISA method to measure 25(OH) D3,
and enrolling the study subjects before measuring 25
(OH) D3 levels, because of which, 6 subjects were ex-
cluded since they were non-deficient.
Conclusion
In conclusion, vitamin D supplementation only repre-
sented the significant effect on 25(OH) D3, PTH, WC and
fat percentage in subjects with coronary heart disease. In
short-term treatment, it is difficult to evaluate the efficacy
of vitamin D supplementation. To confirm the beneficial
effect of vitamin D on health outcomes, longitudinal clin-
ical trials are required. We recommended future studies
to assess the effect of vitamin D supplementation on an-
other types of HSPs in CVD patients in a larger sample
size and longer follow-up period. The results of this study
can be used in future studies with similar theme of re-
search, and health-related strategic planning for CVD in
countries with similar socioeconomic, cultural, and vita-
min D deficiency prevalence.
Table 3 Sun Exposure and Physical Activity at Baseline and After Intervention
Placebo (35 patient) Vitamin D (32 patient) P value1
Sun exposure
Baseline
less than 1 h/day 19 (54.30) 20 (62.50) 0.496
more than 1 h/day 16 (45.70) 12 (37.50)
Endpoint
less than 1 h/day 19 (54.30) 18 (56.30) 0.872
more than 1 h/day 16 (45.70) 14 (43.80)
Physical Activity (MET-minute/Week)
Baseline
Light 22 (62.90) 21 (65.60) 0.813
moderate & vigorous 13 (37.10) 11 (34.40)
Endpoint
Light 19 (54.30) 16 (50) 0.726
moderate & vigorous 16 (45.70) 16 (50)
1Between-group P values based on Chi- square test
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